Dosing & Administration for Chronic ITP

Help your patients reach their chronic ITP treatment goals.

Doptelet Platelet Characters in the Woods
Air Ballon

Titrate with one pill strength

Start patients with a dosage strength of 20 mg once daily and dose adjust as needed1*†‡

Appropriate for a range of patient types1

  • No dose restrictions necessary for different ancestry demographics§ 

  • No additional precautions for individuals with cataracts

  • No known statin interactions

  • Not an immunosuppressant therapy

American Society of Hematology Logo

The American Society of Hematology (ASH) guidelines recommend a single course of ≤6 weeks of steroids when prescribing for newly diagnosed adults with chronic ITP.2

Dosing and titration schedule1

Doptelet Dosing and Titration Schedule for ITP
Medicine Bottle Icon

Use the lowest dose of Doptelet needed to achieve and maintain a platelet count of ≥50x109/L. 
Dose adjustments are based on platelet count.1

*Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 20 mg 3 times a week; start patients taking moderate or strong dual inducers of CYP2C9 and CYP3A4 with 40 mg once daily. Please see Full Prescribing Information for additional information on dose adjustments.1

†After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts monthly thereafter. Obtain platelet counts weekly for at least 4 weeks following discontinuation of Doptelet.1

‡After adjusting dosage, wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.1

§Doptelet has demonstrated safety in patients of Asian descent without the need for special dosing; no dose adjustments necessary for different conditions and population demographics.1

Titration Calculator1

Want more information on dosing & titration?
Answer these 3 questions:

1

I’m looking for dosing recommendations for:

Starting patients on Doptelet Titrating for a patient
already taking Doptelet
2

Is your patient taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4?

Yes No
2

What is your patient’s platelet count?
Platelet count (x109/L)

Below goal: <50 after
2 weeks of treatment At goal: 50-200 Above goal: 201-400 Above goal: >400
3

My patient is taking:

Moderate or strong dual inhibitors of CYP2C9 and CYP3A4 Moderate or strong dual inducers of CYP2C9 and CYP3A4
3

My patient is currently taking Doptelet at this dosage strength:

LEVEL 1
20 mg
once a week
LEVEL 2
20 mg
twice a week
OR
40 mg
once a week
LEVEL 3
20 mg
3 times a week
LEVEL 4
20 mg
once a day
LEVEL 5
40 mg
3 times a week
AND
20 mg on
4 remaining days
LEVEL 6
40 mg
once a day
Result

Recommended starting dose:
20 mg once daily.

New Calculation

Doptelet Platelet Characters Sitting Down with a Cheese Board

Taken on their terms1,3,4

Doptelet is the only oral TPO-RA of its kind that your patients can take based on their schedule.

  • Patients are required to take Doptelet with food and on a consistent schedule

  • Patients can take Doptelet at home

Set chronic ITP treatment goals from the start

  • One goal of chronic ITP treatment is to increase and maintain a stable platelet count

  • Additional factors to consider when discussing treatment goals with your patients include the duration of ITP, frequency of bleeding episodes, increased risk factors for thromboembolism, comorbidities, age, medication adherence, support networks, patient preference, cost, and availability

Doptelet Platelet Tourist Characters

Help your patients get access to Doptelet

Explore all the Doptelet resources to learn how you can help.

VIEW ACCESS & RESOURCES

  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  3. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2022.
  4. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021.